Faron Pharmaceuticals Oy has announced the exercise of options and the expected admission of new ordinary shares, which will rank pari passu with existing ordinary shares. The enlarged issued number of shares following registration will be 68,807,199 ordinary shares with voting rights attached. The company has no shares in treasury, and the total number of voting rights in Faron will be 68,807,199. The BEXMAB study is an open-label Phase 1/2 clinical trial investigating bexmarilimab in combination with standard of care in the aggressive hematological malignancies of acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). Bexmarilimab is Faron's wholly owned, investigational immunotherapy designed to overcome resistance to existing treatments and optimize clinical outcomes by targeting myeloid cell function and igniting the immune system. Faron Pharmaceuticals is a global, clinical-stage biopharmaceutical company focused on tackling cancers via novel immunotherapies, with its lead asset being bexmarilimab, a novel anti-Clever-1 humanized antibody.